Basel-based Windward Bio filed for a Nasdaq IPO to fund two China-derived assets and in-house R&D.
endpoints.newsSwiss biotech Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&DBasel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
1 repost1 like